Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
The data describes the results of a comparative study that highlights cost-related healthcare resource utilization data (HCRU) in DGP patients taking GIMOTI (nasal metoclopramide) versus those on oral metoclopramide over a six-month period.
- The data describes the results of a comparative study that highlights cost-related healthcare resource utilization data (HCRU) in DGP patients taking GIMOTI (nasal metoclopramide) versus those on oral metoclopramide over a six-month period.
- HCRU is the description and quantification of patients’ total usage of healthcare services such as emergency department (ED) visits, hospitalization or how often they visit a healthcare provider in the office.
- The cost to the patients and the healthcare system is significant and the impact is considerable for all parties involved.
- The data for GIMOTI continues to reinforce those providers can and should strive to improve outcomes for patients,” commented Chris Quesenberry, GIMOTI Chief Commercial Officer.